Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xycrobes
- Development stage
- Preclinical
- Lead developer
- Revance
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
Xycrobes are a live biotherapeutic technology platform consisting of engineered skin-derived commensal bacteria. Developed by Xycrobe Therapeutics and acquired by Crown Laboratories, the technology is commercialized under the brand name BIOJUVE™. [8, 9] The active ingredient is a specific living strain of beneficial bacteria, *Cutibacterium acnes subspecies defendens* (strain XYCM42). [3, 7] These microbes are delivered topically, where they live on the skin and in follicles to naturally produce and deliver biotherapeutics such as proteins, antioxidants, and anti-inflammatory mediators. [2] The technology is designed to beneficially modulate the skin microbiome to treat inflammatory skin conditions and signs of aging by replacing pathogenic flora with beneficial microbes, consuming excess oil, and releasing skin-healthy molecules. [4, 6]
- Brand names
- XycrobesBIOJUVE
02
Targets
IL10RA (Interleukin-10 Receptor)
Beyond the preview
Go deeper on Xycrobes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xycrobes.